Transmission & Prevention
· Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US: Center for Disease Control and Prevention (CDC) reviewed Vaccine Adverse Event Reporting System (VAERS) data for anaphylaxis after receiving the Pfizer-BioTech (n= 9,943,247) or Moderna (n= 7,581,429) COVID-19 vaccine and found rates of 4.7 cases/million for Pfizer-Biotech and 2.5 cases/million for Moderna. There were no deaths reported after receiving Pfizer-BioTech or Moderna vaccinations and with rare anaphylaxis rates, the benefits of vaccination far outweigh the risks of anaphylaxis, especially compared to the context of morbidity and mortality from COVID-19 infection.
Adjusting Practice During COVID-19
Involving Pregnant Individuals in Clinical Research on COVID-19 Vaccines: Physician and doctorate researchers associated with the National Institutes of Health (NIH) describe the risks of pregnant and lactating people getting COVID-19. These include an increased risk of hospitalization, cesarean delivery (RR=1.57), postpartum hemorrhage (RR=2.04), hypertensive disorders (RR=1.64), and preterm birth (RR=3.53). The authors express concern over the lack of inclusion of pregnant and lactating people in SARS-CoV-2 vaccine clinical trials.
Click here to download the full report.